Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results